Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 43

1.
2.

International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency.

Farkas H, Martinez-Saguer I, Bork K, Bowen T, Craig T, Frank M, Germenis AE, Grumach AS, Luczay A, Varga L, Zanichelli A; HAWK..

Allergy. 2017 Feb;72(2):300-313. doi: 10.1111/all.13001.

3.

Diagnosis and screening of patients with hereditary angioedema in primary care.

Henao MP, Kraschnewski JL, Kelbel T, Craig TJ.

Ther Clin Risk Manag. 2016 May 2;12:701-11. doi: 10.2147/TCRM.S86293. Review.

4.

A Crossover Design for Comparative Efficacy: A 36-Week Randomized Trial of Bevacizumab and Ranibizumab for Diabetic Macular Edema.

Wiley HE, Thompson DJ, Bailey C, Chew EY, Cukras CA, Jaffe GJ, Lee RW, Loken EK, Meyerle CB, Wong W, Ferris FL 3rd.

Ophthalmology. 2016 Apr;123(4):841-9. doi: 10.1016/j.ophtha.2015.11.021.

PMID:
26875003
5.

New insight into the effects of heparinoids on complement inhibition by C1-inhibitor.

Poppelaars F, Damman J, de Vrij EL, Burgerhof JG, Saye J, Daha MR, Leuvenink HG, Uknis ME, Seelen MA.

Clin Exp Immunol. 2016 Jun;184(3):378-88. doi: 10.1111/cei.12777. Epub 2016 Apr 13.

6.

The factor XIIa blocking antibody 3F7: a safe anticoagulant with anti-inflammatory activities.

Worm M, Köhler EC, Panda R, Long A, Butler LM, Stavrou EX, Nickel KF, Fuchs TA, Renné T.

Ann Transl Med. 2015 Oct;3(17):247. doi: 10.3978/j.issn.2305-5839.2015.09.07. Review.

7.

Hereditary Angioedema and Gastrointestinal Complications: An Extensive Review of the Literature.

Patel N, Suarez LD, Kapur S, Bielory L.

Case Reports Immunol. 2015;2015:925861. doi: 10.1155/2015/925861.

8.

Therapeutic application of C1 esterase inhibitor concentrate for clinical amniotic fluid embolism: a case report.

Todo Y, Tamura N, Itoh H, Ikeda T, Kanayama N.

Clin Case Rep. 2015 Jul;3(7):673-5. doi: 10.1002/ccr3.316.

9.

Defective glycosylation of coagulation factor XII underlies hereditary angioedema type III.

Björkqvist J, de Maat S, Lewandrowski U, Di Gennaro A, Oschatz C, Schönig K, Nöthen MM, Drouet C, Braley H, Nolte MW, Sickmann A, Panousis C, Maas C, Renné T.

J Clin Invest. 2015 Aug 3;125(8):3132-46. doi: 10.1172/JCI77139.

10.

Recent advances in renal transplantation: antibody-mediated rejection takes center stage.

Pouliquen E, Koenig A, Chen CC, Sicard A, Rabeyrin M, Morelon E, Dubois V, Thaunat O.

F1000Prime Rep. 2015 May 12;7:51. doi: 10.12703/P7-51. Review.

11.

Recombinant human C1 esterase inhibitor in the management of hereditary angioedema.

Riedl M.

Clin Drug Investig. 2015 Jul;35(7):407-17. doi: 10.1007/s40261-015-0300-z. Review.

12.

Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1-inhibitor concentrate.

Zuraw BL, Cicardi M, Longhurst HJ, Bernstein JA, Li HH, Magerl M, Martinez-Saguer I, Rehman SM, Staubach P, Feuersenger H, Parasrampuria R, Sidhu J, Edelman J, Craig T.

Allergy. 2015 Oct;70(10):1319-28. doi: 10.1111/all.12658.

13.

Efficacy of C1 esterase inhibitor concentrate in treatment of cutaneous attacks of hereditary angioedema.

Bork K, Craig TJ, Bernstein JA, Feuersenger H, Machnig T, Staubach P.

Allergy Asthma Proc. 2015 May-Jun;36(3):218-24. doi: 10.2500/aap.2015.36.3844.

14.

Prevalence of hereditary angioedema in untested first-degree blood relatives of known subjects with hereditary angioedema.

Riedl MA, Lumry WR, Busse P, Levy H, Steele T, Dayno J, Li HH.

Allergy Asthma Proc. 2015 May-Jun;36(3):206-12. doi: 10.2500/aap.2015.36.3833.

15.

C1 inhibitor deficiency: 2014 United Kingdom consensus document.

Longhurst HJ, Tarzi MD, Ashworth F, Bethune C, Cale C, Dempster J, Gompels M, Jolles S, Seneviratne S, Symons C, Price A, Edgar D.

Clin Exp Immunol. 2015 Jun;180(3):475-83. doi: 10.1111/cei.12584. Erratum in: Clin Exp Immunol. 2015 Dec;182(3):346.

16.

Frequency of the virilising effects of attenuated androgens reported by women with hereditary angioedema.

Zotter Z, Veszeli N, Csuka D, Varga L, Farkas H.

Orphanet J Rare Dis. 2014 Dec 5;9:205. doi: 10.1186/s13023-014-0205-6.

17.

Hereditary angioedema: what the gastroenterologist needs to know.

Ali MA, Borum ML.

Clin Exp Gastroenterol. 2014 Nov 20;7:435-45. doi: 10.2147/CEG.S50465. Review.

18.

Canadian hereditary angioedema guideline.

Betschel S, Badiou J, Binkley K, Hébert J, Kanani A, Keith P, Lacuesta G, Yang B, Aygören-Pürsün E, Bernstein J, Bork K, Caballero T, Cicardi M, Craig T, Farkas H, Longhurst H, Zuraw B, Boysen H, Borici-Mazi R, Bowen T, Dallas K, Dean J, Lang-Robertson K, Laramée B, Leith E, Mace S, McCusker C, Moote B, Poon MC, Ritchie B, Stark D, Sussman G, Waserman S.

Allergy Asthma Clin Immunol. 2014 Oct 24;10(1):50. doi: 10.1186/1710-1492-10-50.

19.

Inhibition of plasma kallikrein by a highly specific active site blocking antibody.

Kenniston JA, Faucette RR, Martik D, Comeau SR, Lindberg AP, Kopacz KJ, Conley GP, Chen J, Viswanathan M, Kastrapeli N, Cosic J, Mason S, DiLeo M, Abendroth J, Kuzmic P, Ladner RC, Edwards TE, TenHoor C, Adelman BA, Nixon AE, Sexton DJ.

J Biol Chem. 2014 Aug 22;289(34):23596-608. doi: 10.1074/jbc.M114.569061.

20.

Improving patient outcomes in hereditary angioedema: reducing attack frequency using routine prevention with C1 inhibitor concentrate.

Dominas N, Hoffmann TK, Bas M, Greve J.

BMJ Case Rep. 2014 May 21;2014. pii: bcr2013200873. doi: 10.1136/bcr-2013-200873.

Supplemental Content

Support Center